Cleared Traditional

K920352 - BIO-DETEK EEG ELECTRODE

K920352 is the FDA 510(k) clearance for BIO-DETEK EEG ELECTRODE by Bio-Detek, Inc.. It is a Class 2 Neurology device (product code GXZ) cleared through the Traditional 510(k) pathway after a 200-day FDA review.

K920352 · Bio-Detek, Inc. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1992
Decision
200d
Days
Class 2
Risk

K920352 is an FDA 510(k) clearance for the BIO-DETEK EEG ELECTRODE. Classified as Electrode, Needle (product code GXZ), Class II - Special Controls.

Submitted by Bio-Detek, Inc. (Attleboro, US). The FDA issued a Cleared decision on August 14, 1992 after a review of 200 days - an extended review cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1350 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all Bio-Detek, Inc. devices

Submission Details

510(k) Number K920352 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 27, 1992
Decision Date August 14, 1992
Days to Decision 200 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
52d slower than avg
Panel avg: 148d · This submission: 200d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GXZ Electrode, Needle
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1350
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.